Cargando…

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation

RATIONALE: A high incidence of GLA IVS4+919 G>A mutation in patients with Fabry disease of the later-onset cardiac phenotype, has been reported in Taiwan. However, suitable biomarkers or potential therapeutic surrogates for Fabry cardiomyopathy (FC) in such patients under enzyme replacement treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chien, Yueh, Chien, Chian-Shiu, Chiang, Huai-Chih, Huang, Wei-Lin, Chou, Shih-Jie, Chang, Wei-Chao, Chang, Yuh-Lih, Leu, Hsin-Bang, Chen, Kuan-Hsuan, Wang, Kang-Ling, Lai, Ying-Hsiu, Liu, Yung-Yang, Lu, Kai-Hsi, Li, Hsin-Yang, Sung, Yen-Jen, Jong, Yuh-Jyh, Chen, Yann-Jang, Chen, Chung-Hsuan, Yu, Wen-Chung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349979/ https://www.ncbi.nlm.nih.gov/pubmed/27888626 http://dx.doi.org/10.18632/oncotarget.13552

Ejemplares similares

Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease
por: Song, Hui-Yung, et al.
Publicado: (2016)

Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease
por: Chang, Wen-Hsin, et al.
Publicado: (2017)

Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy
por: Song, Hui-Yung, et al.
Publicado: (2019)

Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients
por: Chien, Yueh, et al.
Publicado: (2018)

Assessment of Fabry variant (IVS4+919G>A) Cardiomyopathy in Taiwanese: Emphasis on T1 mapping
por: Chang, Yu-pin, et al.
Publicado: (2016)

MRI assessment of cardiomyopathy in Taiwan Chinese late-onset Fabry mutation (IVS4+919G>A)
por: Chang, Yu-Pin, et al.
Publicado: (2015)

Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
por: Lin, Hsiang-Yu, et al.
Publicado: (2013)

Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation
por: Song, Hui-Yung, et al.
Publicado: (2021)

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)
por: Hsu, Ting-Rong, et al.
Publicado: (2014)

Fabry disease due to D313Y and novel GLA mutations
por: Koulousios, Konstantinos, et al.
Publicado: (2017)

Functional evaluation of a novel GLA causative mutation in Fabry disease
por: Li, Ping, et al.
Publicado: (2019)

Novel GLA Mutation Promotes Intron Inclusion Leading to Fabry Disease
por: Varela, Patrícia, et al.
Publicado: (2019)

Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene
por: Hossain, Mohammad Arif, et al.
Publicado: (2019)

Dual DNA Transfection Using 1,6-Hexanedithiol-Conjugated Maleimide-Functionalized PU-PEI(600) For Gene Correction in a Patient iPSC-Derived Fabry Cardiomyopathy Model
por: Chien, Chian-Shiu, et al.
Publicado: (2021)

Correction: Fabry disease due to D313Y and novel GLA mutations
Publicado: (2018)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
por: Liu, Hao-Chuan, et al.
Publicado: (2014)

GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
por: Chaves-Markman, Ândrea Virgínia, et al.
Publicado: (2019)

Abnormal Pre-mRNA Splicing in Exonic Fabry Disease-Causing GLA Mutations
por: Alfen, Franziska, et al.
Publicado: (2022)

The Comparison of Environmental Effects on Michelson and Fabry-Perot Interferometers Utilized for the Displacement Measurement
por: Wang, Yung-Cheng, et al.
Publicado: (2010)

Renal variant of Fabry disease with sporadic GLA gene mutation: role of early renal biopsy
por: Al-Salam, Suhail, et al.
Publicado: (2012)

Description of a New GLA Gene Variant in a Patient with Hypertrophic Cardiomyopathy. Is it Fabry Disease?
por: Bittencourt, Marcelo Imbroinise
Publicado: (2019)

Identification of a Novel GLA Mutation (L206 P) in a Patient with Fabry Disease
por: Kim, Ji-Hoon, et al.
Publicado: (2017)

An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene
por: Sarsam, Luay, et al.
Publicado: (2020)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation
por: Valtola, Kati, et al.
Publicado: (2023)

Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey
por: Hsu, Ting-Rong, et al.
Publicado: (2017)

Impaired ROS Scavenging System in Human Induced Pluripotent Stem Cells Generated from Patients with MERRF Syndrome
por: Chou, Shih-Jie, et al.
Publicado: (2016)

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
por: Germain, Dominique P., et al.
Publicado: (2018)

Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report
por: Chong, Yosep, et al.
Publicado: (2016)

A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation
por: Lee, Han-Jui, et al.
Publicado: (2017)

Broad spectrum of Fabry disease manifestation in an extended Spanish family with a new deletion in the GLA gene
por: Lukas, Jan, et al.
Publicado: (2012)

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y
por: Oder, Daniel, et al.
Publicado: (2016)

Assessment of Peripheral Nervous System Alterations in Patients with the Fabry Related GLA-Variant p.A143T
por: Godel, Tim, et al.
Publicado: (2020)

Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease
por: Kaneski, Christine R., et al.
Publicado: (2022)

The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants
por: Sánchez, Rosario, et al.
Publicado: (2023)

The potential consequences of bidirectional promoter methylation on GLA and HNRNPH2 expression in Fabry disease phenotypes in a family of patients carrying a GLA deletion variant
por: Al-Obaide, Mohammed A., et al.
Publicado: (2022)

Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease
por: Zhou, Chi, et al.
Publicado: (2018)

Fabry Disease that Phenocopies Hypertrophic Cardiomyopathy: a thorough Genetic ‘Detective’ Identifies the ‘Rogue’ Hidden in the GLA Gene
por: Kwon, Soonil, et al.
Publicado: (2019)

Detection of single nucleotide and copy number variants in the Fabry disease-associated GLA gene using nanopore sequencing
por: Nowak, Albina, et al.
Publicado: (2021)

p.R220L Is a Likely Pathogenic Novel GLA Gene Mutation Responsible for Fabry Disease
por: Ali Barman, Hasan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ops9erbv7jlourakmcb938t45t